Session IV: Autologous stem cell transplantation in hematologic malignancies: multiple myeloma
نویسندگان
چکیده
منابع مشابه
Stem Cell Transplantation for Hematologic Malignancies
Histocompatibility in transplantation is governed by the products of the human leucocyte antigen (HLA) genes encoded within the major histocompatibility complex (MHC) on chromosome 6p21. HLA antigens define tissue type and are inherited en bloc in classical Mendelian fashion. Genotypically identical siblings inherit the same paternal and maternal chromosome 6. Haploidentical relatives share one...
متن کاملSingle versus double autologous stem-cell transplantation for multiple myeloma.
BACKGROUND We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS A complete or a very good partial resp...
متن کاملAutologous stem cell transplantation for multiple myeloma: history and future
Over the last decade, high-dose therapy supported by autologous stem cell transplantation (ASCT) has been the standard frontline therapy for younger patients with multiple myeloma (MM). But recently, the treatment strategy has been dramatically changed after the introduction of novel agents such as thalidomide, bortezomib and lenalidomide. These agents have been incorporated into induction ther...
متن کاملAutologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is considered the standard of care for multiple myeloma patients who are eligible for transplantation. The process of autografting comprises the following steps: control of the primary disease by using a certain induction therapeutic protocol, mobilization of stem cells, collection of mobilized stem cells by a...
متن کاملLow transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.
BACKGROUND AND OBJECTIVES Patients over 60 years are frequently excluded from autologous stem cell transplantation (ASCT) programs due to a traditionally high rate of transplant-related mortality (TRM) in such indications. We evaluated the results of ASCT in a group of 49 patients >= 60 years of age [32 males, median age 63 years (range, 60 to 71)] autografted in our institution from January 19...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bone Marrow Transplantation
سال: 1999
ISSN: 0268-3369,1476-5365
DOI: 10.1038/sj.bmt.1701839